Hu Chunxiu, Kong Hongwei, Qu Fengxue, Li Yong, Yu Zhenqiu, Gao Peng, Peng Shuangqing, Xu Guowang
CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, PR China.
Mol Biosyst. 2011 Dec;7(12):3271-9. doi: 10.1039/c1mb05342f. Epub 2011 Oct 18.
Hypertension is a key risk factor in the progression of cardiovascular disease (CVD). Dyslipidemia, a strong predictor of CVD, frequently coexists with hypertension. Therefore, the control of hypertension and dyslipidemia may help reduce CVD morbidity and mortality. In the present study, the therapeutic effects of antihypertensive agents on blood pressure control and plasma lipid metabolism were evaluated. The plasma lipid profiles of patients with treated (n = 25) or untreated (n = 30) essential hypertension as well as of subjects with normotension (n = 28) were analyzed using liquid chromatography mass spectrometry. Principal component analysis of the lipidomics data revealed distinct clusters among studied subjects across three human populations. Phosphatidylcholines and triacylglycerols (TG) dominated the pattern of hypertension-influenced plasma lipid metabolism. Discriminatory lipid metabolites were analyzed using one-way analysis of variance followed by a post hoc multiple comparison correction. TG lipid class was significantly increased by 49.0% (p < 0.001) in hypertensive vs. normotensive groups while tended to decrease (-21.2%, p = 0.054) in hypertensive patients after treatment. Total cholesteryl esters were significantly decreased by -16.9% (p < 0.001) in hypertensive patients after treatment. In particular, a large number of individual neutral lipid species were significantly elevated in hypertensive subjects but significantly decreased after treatment with antihypertensive agents. The present study applied, for the first time, a systems biology based lipidomics approach to investigate differentiation among plasma lipid metabolism of patients with treated/untreated essential hypertension and subjects with normotension. Our results demonstrate that antihypertensive medications to lower blood pressure of hypertensive patients to target levels produced moderate plasma lipid metabolism improvement of patients with hypertension.
高血压是心血管疾病(CVD)进展中的关键危险因素。血脂异常是CVD的一个强有力预测指标,常与高血压并存。因此,控制高血压和血脂异常可能有助于降低CVD的发病率和死亡率。在本研究中,评估了抗高血压药物对血压控制和血浆脂质代谢的治疗效果。使用液相色谱质谱法分析了经治疗(n = 25)或未经治疗(n = 30)的原发性高血压患者以及血压正常者(n = 28)的血浆脂质谱。脂质组学数据的主成分分析揭示了三个不同人群中研究对象之间的明显聚类。磷脂酰胆碱和三酰甘油(TG)主导了受高血压影响的血浆脂质代谢模式。使用单因素方差分析,随后进行事后多重比较校正,分析了具有鉴别意义的脂质代谢物。与血压正常组相比,高血压组的TG脂质类别显著增加49.0%(p < 0.001),而高血压患者治疗后TG脂质类别有下降趋势(-21.2%,p = 0.054)。治疗后高血压患者的总胆固醇酯显著下降-16.9%(p < 0.001)。特别是,大量个体中性脂质种类在高血压患者中显著升高,但在使用抗高血压药物治疗后显著下降。本研究首次应用基于系统生物学的脂质组学方法来研究经治疗/未经治疗的原发性高血压患者与血压正常者血浆脂质代谢的差异。我们的结果表明,将高血压患者的血压降至目标水平的抗高血压药物可使高血压患者的血浆脂质代谢得到适度改善。